

REFERENCE TITLE: bulk drug substances; prohibitions

State of Arizona
House of Representatives
Fifty-seventh Legislature
Second Regular Session
2026

HB 4036

Introduced by
Representative Peña

AN ACT

AMENDING TITLE 32, CHAPTER 18, ARTICLE 3, ARIZONA REVISED STATUTES, BY
ADDING SECTION 32-1971.01; RELATING TO THE ARIZONA STATE BOARD OF
PHARMACY.

(TEXT OF BILL BEGINS ON NEXT PAGE)

1 Be it enacted by the Legislature of the State of Arizona:

2 Section 1. Title 32, chapter 18, article 3, Arizona Revised
3 Statutes, is amended by adding section 32-1971.01, to read:

4 32-1971.01. Compounded medications; records; inspections;
5 bulk drug substances; prohibitions; deceptive
6 advertising; penalties; rules; definitions

7 A. IT IS UNLAWFUL FOR ANY PERSON OR ENTITY TO ENGAGE IN THE SALE,
8 TRANSFER OR DISTRIBUTION OF A DRUG COMPOUNDED UNDER SECTION 503A OF THE
9 FEDERAL FOOD, DRUG, AND COSMETIC ACT (21 UNITED STATES CODE SECTION 353a)
10 USING A DRUG SUBSTANCE THAT IS A GLUCOSE-DEPENDENT INSULINOTROPIC
11 POLYPEPTIDE RECEPTOR OR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USED FOR
12 OBESITY OR WEIGHT MANAGEMENT OR A DRUG SUBSTANCE THAT IS A COMPONENT OF A
13 SIMILAR DRUG APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION
14 FOR OBESITY OR WEIGHT MANAGEMENT UNLESS THE COMPOUNDER OF THE DRUG:

15 1. USES BULK DRUG SUBSTANCES THAT COMPLY WITH THE STANDARDS OF AN
16 APPLICABLE UNITED STATES PHARMACOPOEIA OR NATIONAL FORMULARY MONOGRAPH, IF
17 A MONOGRAPH EXISTS, AND THE UNITED STATES PHARMACOPOEIA CHAPTER ON
18 PHARMACY COMPOUNDING OR, IF A NATIONAL FORMULARY MONOGRAPH DOES NOT EXIST,
19 THE BULK DRUG SUBSTANCES EITHER:

20 (a) ARE DRUG SUBSTANCES THAT ARE COMPONENTS OF DRUGS APPROVED BY
21 THE UNITED STATES FOOD AND DRUG ADMINISTRATION.

22 (b) APPEAR ON THE LIST DEVELOPED BY THE UNITED STATES FOOD AND DRUG
23 ADMINISTRATION PURSUANT TO 21 UNITED STATES CODE SECTION
24 353a(b)(1)(A)(i)(III).

25 2. IF THE LABELING OF A DRUG APPROVED BY THE UNITED STATES FOOD AND
26 DRUG ADMINISTRATION SPECIFIES A PROCESS FOR MANUFACTURING THE BULK DRUG
27 SUBSTANCE, CONFIRMS THAT ANY BULK DRUG SUBSTANCE USED WAS MANUFACTURED
28 ACCORDING TO THE PROCESS PRESCRIBED BY FEDERAL LAW.

29 3. ENSURES THAT THE BULK DRUG SUBSTANCE IS A PHARMACEUTICAL GRADE
30 PRODUCT.

31 4. VERIFIES THAT THE BULK DRUG SUBSTANCE IS ACCOMPANIED BY A VALID
32 CERTIFICATE OF ANALYSIS.

33 5. CONDUCTS AND DOCUMENTS QUALITY CONTROL TESTING OF ANY BULK DRUG
34 SUBSTANCE BEFORE ITS USE IN A COMPOUNDED DRUG TO CONFIRM THE IDENTITY AND
35 CONTENT OF THE BULK DRUG SUBSTANCE AND THE NAME AND QUANTITY OF EACH
36 IMPURITY PRESENT IN THE BULK DRUG SUBSTANCE IN AN AMOUNT THAT EXCEEDS
37 ONE-TENTH OF ONE PERCENT.

38 6. CONDUCTS AND DOCUMENTS QUALITY CONTROL TESTING OF THE FINISHED
39 DRUG PRODUCT COMPOUNDED IN BATCHES BEFORE RELEASE AND AT EXPIRY FOR ANY
40 IMPURITIES DERIVED FROM THE USE OF THE BULK DRUG SUBSTANCE, INCLUDING THE
41 CHEMICAL NAME AND QUANTITIES OF ANY SUCH IMPURITIES.

42 7. OBTAINS PROOF THAT THE MANUFACTURE OF THE BULK DRUG SUBSTANCE
43 TOOK PLACE IN AN ESTABLISHMENT THAT MEETS ALL OF THE FOLLOWING:

44 (a) IS DULY REGISTERED WITH THE UNITED STATES FOOD AND DRUG
45 ADMINISTRATION PURSUANT TO 21 UNITED STATES CODE SECTION 360.

1 (b) HAS UNDERGONE AN INSPECTION BY THE UNITED STATES FOOD AND DRUG
2 ADMINISTRATION AS A HUMAN DRUG ESTABLISHMENT WITHIN THE LAST TWO YEARS.

3 (c) IS NOT SUBJECT TO AN IMPORT ALERT BY THE UNITED STATES FOOD AND
4 DRUG ADMINISTRATION.

5 8. COMPLIES WITH THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

6 B. IT IS UNLAWFUL FOR ANY MANUFACTURER OR WHOLESALER TO SELL,
7 TRANSFER OR DISTRIBUTE A BULK DRUG SUBSTANCE IN THIS STATE FOR USE IN
8 COMPOUNDING WITHOUT PROVIDING TO THE PURCHASER:

9 1. WRITTEN VERIFICATION THAT THE BULK DRUG SUBSTANCE IS
10 PHARMACEUTICAL GRADE AND MEETS THE SOURCING REQUIREMENTS.

11 2. DOCUMENTATION OF ANY QUALITY CONTROL TESTING AND THE VALID
12 CERTIFICATE OF ANALYSIS AS REQUIRED BY SUBSECTION A, PARAGRAPH 4 OF THIS
13 SECTION.

14 C. ANY PERSON OR ENTITY ENGAGING IN THE SALE, TRANSFER OR
15 DISTRIBUTION OF COMPOUNDED DRUGS PURSUANT TO SUBSECTION A OF THIS SECTION
16 SHALL MAINTAIN ALL RECORDS RELATED TO THE ACQUISITION, EXAMINATION AND
17 TESTING OF THE BULK DRUG SUBSTANCE FOR AT LEAST TWO YEARS AFTER THE
18 EXPIRATION DATE OF THE LAST LOT OF DRUG CONTAINING THE BULK DRUG SUBSTANCE
19 AND, ON REQUEST BY THE BOARD, SHALL FURNISH THE RECORDS TO THE BOARD
20 WITHIN ONE BUSINESS DAY AFTER RECEIVING THE REQUEST OR WITHIN A REASONABLE
21 TIME AS DETERMINED BY THE BOARD BASED ON THE CIRCUMSTANCES OF THE REQUEST.

22 D. THE BOARD OR THE BOARD'S AUTHORIZED AGENT HAS THE AUTHORITY TO
23 INSPECT ANY PERSON OR ENTITY THAT ENGAGES IN COMPOUNDING DRUGS, AS WELL
24 ANY DOMESTIC SUPPLIER, WHOLESALER, REPACKAGER OR OTHER PROVIDER OF THE
25 BULK DRUG SUBSTANCE FOR COMPOUNDING, FOR COMPLIANCE WITH THE REQUIREMENTS
26 PRESCRIBED IN SUBSECTION A OF THIS SECTION. REFUSAL TO ALLOW THE BOARD OR
27 THE BOARD'S AUTHORIZED AGENT ACCESS TO CONDUCT AN INSPECTION CONSTITUTES A
28 VIOLATION OF THIS SECTION.

29 E. IT IS UNLAWFUL FOR ANY PERSON TO ADVERTISE OR OTHERWISE PROMOTE
30 COMPOUNDED MEDICATIONS UNLESS THE ADVERTISEMENT IS TRUTHFUL AND NOT
31 MISLEADING. AN ADVERTISEMENT IS NOT TRUTHFUL AND IS MISLEADING IF IT
32 INCLUDES ANY UNSUBSTANTIATED CLAIM WITH RESPECT TO THE PRODUCT. AN
33 ADVERTISEMENT IS MISLEADING UNLESS IT CONTAINS ALL OF THE FOLLOWING:

34 1. A DISCLOSURE OF THE POTENTIAL SIDE EFFECTS, ADVERSE REACTIONS,
35 CONTRAINDICATIONS, PRECAUTIONS AND WARNINGS ASSOCIATED WITH ACTIVE
36 INGREDIENTS IN THE MEDICATION, INCLUDING ANY NOTED FROM CLINICAL TRIALS,
37 RESEARCH AND OTHER APPROPRIATE INFORMATION SOURCES.

38 2. A SUMMARY OF THE SPECIFIED RISK INFORMATION IN THE LABELING OF
39 THE UNITED STATES FOOD AND DRUG ADMINISTRATION-APPROVED DRUG, IF
40 APPLICABLE, IF THE COMPOUNDED DRUG CONTAINS AN ACTIVE INGREDIENT THAT IS
41 NAMED AS AN ACTIVE INGREDIENT IN A UNITED STATES FOOD AND DRUG
42 ADMINISTRATION-APPROVED DRUG.

43 3. IF APPLICABLE, A CLEAR, CONSPICUOUS STATEMENT THAT THE PRODUCT
44 IS A COMPOUNDED MEDICATION, HAS NOT BEEN APPROVED BY THE UNITED STATES

1 FOOD AND DRUG ADMINISTRATION AND HAS NOT BEEN EVALUATED BY THE UNITED
2 STATES FOOD AND DRUG ADMINISTRATION FOR SAFETY OR EFFICACY.

3 F. IN ADDITION TO ANY OTHER PENALTIES PRESCRIBED IN THIS CHAPTER, A
4 PERSON OR ENTITY THAT VIOLATES THIS SECTION MAY BE SUBJECT TO:

5 1. A CIVIL PENALTY OF \$1,000 PER DOSE OF THE ILLEGALLY COMPOUNDED
6 DRUG SOLD, TRANSFERRED OR DISTRIBUTED.

7 2. A SUSPENSION OR REVOCATION OF THE LICENSEE'S OR PERMITTEE'S
8 LICENSE OR PERMIT, AS APPLICABLE.

9 G. THE BOARD SHALL ADOPT RULES AS NECESSARY TO IMPLEMENT THIS
10 SECTION.

11 H. FOR THE PURPOSES OF THIS SECTION:

12 1. "BULK DRUG SUBSTANCE":

13 (a) MEANS ANY SUBSTANCE THAT IS INTENDED FOR INCORPORATION INTO A
14 FINISHED DRUG PRODUCT AND THAT IS INTENDED TO FURNISH PHARMACOLOGICAL
15 ACTIVITY OR ANOTHER DIRECT EFFECT IN THE DIAGNOSIS, CURE, MITIGATION,
16 TREATMENT OR PREVENTION OF A DISEASE, OR TO AFFECT THE STRUCTURE OR ANY
17 FUNCTION OF THE BODY.

18 (b) DOES NOT INCLUDE INTERMEDIATES USED IN THE SYNTHESIS OF THE
19 SUBSTANCE.

20 2. "PERSON" MEANS ANY INDIVIDUAL, PARTNERSHIP, FIRM, CORPORATION OR
21 OTHER LEGAL ENTITY.

22 3. "UNSUBSTANTIATED CLAIM" MEANS ANY STATEMENT, REPRESENTATION OR
23 ASSERTION CONCERNING THE SAFETY, EFFICACY OR OTHER ATTRIBUTES OF A DRUG
24 THAT IS NOT SUPPORTED BY COMPETENT AND RELIABLE SCIENTIFIC EVIDENCE.

25 Sec. 2. Legislative findings

26 The legislature finds the following:

27 1. The safety and integrity of compounded medications are paramount
28 for the health and well-being of residents of this state.

29 2. The United States food and drug administration sets
30 internationally recognized standards for drug approval and regulatory
31 oversight. However, there have been increasing attempts by unscrupulous
32 actors to circumvent these regulations, undermining public trust and
33 patient safety.

34 3. Foreign entities, including those from countries such as China,
35 have exploited regulatory gaps to introduce inferior or contaminated
36 active pharmaceutical ingredients into the supply chain for medications
37 intended for compounding.

38 4. Recent cases, such as those involving medications for weight
39 loss, have demonstrated that high demand can lead to the proliferation of
40 use of illicit, substandard and potentially harmful active pharmaceutical
41 ingredients, also known as bulk drug substances, jeopardizing patient
42 health and safety.

43 5. While the United States food and drug administration bears
44 responsibility for enforcing federal laws to protect citizens from

1 misbranded and adulterated pharmaceutical ingredients, enforcement has
2 proven insufficient to curtail the influx of these substances.

3 6. Even after the United States food and drug administration took
4 some action to curb imports of active pharmaceutical ingredients for
5 weight loss medications from entities that are not compliant with current
6 good manufacturing practice requirements, patients in this state remain at
7 risk of receiving compounded medications containing active pharmaceutical
8 ingredients produced by entities that the United States food and drug
9 administration found to not be compliant with those requirements,
10 including active pharmaceutical ingredients imported into the United
11 States before the United States food and drug administration took action.

12 7. Therefore, it is necessary for this state to take action to
13 protect its residents by ensuring that all active pharmaceutical
14 ingredients used in compounding are sourced from reputable, registered and
15 inspected establishments, and that only pharmaceutical grade, safe and
16 pure ingredients are used in medications for weight loss.